We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
-11.7%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$308M
AUM Growth
+$121M
Cap. Flow
+$155M
Cap. Flow %
50.3%
Top 10 Hldgs %
76.16%
Holding
37
New
5
Increased
13
Reduced
15
Closed
4

Top Buys

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$58.1M
2
TVTX icon
Travere Therapeutics
TVTX
+$18.3M
3
CLDX icon
Celldex Therapeutics
CLDX
+$16.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$16.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.4M

Top Sells

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$5.59M
2
ZGNX
Zogenix, Inc.
ZGNX
+$3.34M
3
LQDA icon
Liquidia Corp
LQDA
+$1.3M
4
COGT icon
Cogent Biosciences
COGT
+$1.29M
5
KRYS icon
Krystal Biotech
KRYS
+$1.03M

Sector Composition

Rank Sector Weight
1 Healthcare 99.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
26
Cabaletta Bio
CABA
$439M
$1.25M 0.41%
616,125
-28,458
-4% -$74.4K
KRYS icon
27
Krystal Biotech
KRYS
$9.88B
$1.22M 0.4%
18,393
-16,423
-47% -$1.03M
OLMA icon
28
Olema Pharmaceuticals
OLMA
$1.02B
$1.2M 0.39%
280,827
-12,972
-4% -$71.5K
CNTB
29
Connect Biopharma Holdings
CNTB
$135M
$688K 0.22%
+227,759
New +$961K
TGTX icon
30
PUT
TG Therapeutics
TGTX
$8.58B
$401K 0.13%
+258,600
New +$2.99M
NGNE icon
31
Neurogene
NGNE
$696M
$264K 0.09%
7,025
-325
-4% -$19K
NKTR icon
32
PUT
Nektar Therapeutics
NKTR
$2.39B
$260K 0.08%
+13,333
New +$1.97M
GYRE icon
33
Gyre Therapeutics
GYRE
$662M
$70K 0.02%
14,145
-654
-4% -$3.24K
ALLK
34
CALL
DELISTED
Allakos
ALLK
– –
-74,500
Closed -$2K
COGT icon
35
Cogent Biosciences
COGT
$6.79B
– –
-150,000
Closed -$1.29M
GBT
36
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-100,000
Closed -$15K
ZGNX
37
DELISTED
Zogenix, Inc.
ZGNX
– –
-205,800
Closed -$3.34M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Kynam Capital Management held 37 positions worth $308M, up 65% from $187M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Kynam Capital Management deployed $155M of net new capital in Q1 2022, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was Natera: 966,400 shares worth $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $5.59M trimmed.

  • Kynam Capital Management's largest Q1 2022 buy was Natera: 966,400 shares worth $39.3M.
  • Kynam Capital Management added most to Travere Therapeutics in Q1 2022, an estimated $18.3M increase.
  • Kynam Capital Management's biggest Q1 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $5.59M.
  • Kynam Capital Management fully exited Zogenix, Inc. in Q1 2022, selling an estimated $3.34M.
  • Kynam Capital Management's ten largest holdings make up 76% of its $308M portfolio in Q1 2022.
  • Kynam Capital Management opened 5 new positions and closed 4 in Q1 2022.
  • Kynam Capital Management's portfolio value rose 65% quarter-over-quarter to $308M.

Based on Kynam Capital Management's 13F filing for Q1 2022, filed 13 May 2022.